Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778798 | 0.90 | SLC6A4 (0.43) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL23778817 | 0.89 | SLC6A4 (0.51) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL22367338 | 0.83 | CACNA2D1 (0.42) | SLC6A2CACNA2D1 | |
| SCHEMBL23778782 | 0.81 | SLC7A5 (0.41) | SLC6A4SLC6A9 | |
| SCHEMBL23778794 | 0.81 | SLC6A4 (0.49) | SLC6A4CACNA2D1 | |
| SCHEMBL23778783 | 0.81 | SLC7A5 (0.41) | SLC6A4SLC6A9 | |
| SCHEMBL19553321 | 0.78 | SLC6A4 (0.47) | SLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL28599710 | 0.77 | SLC6A4 (0.41) | SLC6A4SLC6A2CACNA2D1SLC6A9 | |
| SCHEMBL15809620 | 0.77 | SLC6A4 (0.42) | SLC6A4SLC6A2 | |
| SCHEMBL20917559 | 0.76 | SLC6A4 (0.45) | SLC6A4SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395254-A1 | NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-12-23 | — | — | US | disclosed |
| EP-3873902-A1 | NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395254-A1 | NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1G, CACNA1I, CACNA1B | SLC6A4 162/4885SLC6A2 38/4885CACNA2D1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.